A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain.

A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Abstract Text:

Wei Wang,Shi Ke,Sunkuk Kwon,Sasidhar Yallampalli,Arlin G Cameron,Kristen E Adams,Michel E Mawad,Eva M Sevick-Muraca,

Optical imaging has great potential for studying molecular recognitions both in vivo and in vitro, yet nuclear imaging is the most effective clinical molecular imaging modality. The combination of optical and nuclear imaging modalities may provide complementary information for improving diagnosis and management of diseases. In this study we developed an optical and nuclear dual-labeled imaging agent, 111In-DTPA-Bz-NH-SA-K(IR-783-S-Ph-CO)-c(CGRRAGGSC)NH2, called DLIA-IL11Ralpha. 111In-DTPA-Bz-NH-SA is the radiotracer moiety; a near-infrared dye IR-783-S-Ph-COOH serves as the fluorescent emitter; and the cyclic peptide c(CGRRAGGSC), which is known to target interleukin 11 receptor alpha-chain (IL-11Ralpha), delivers the desired imaging agent to its target. Experiments revealed that the cyclic peptide c(CGRRAGGSC) continued to possess the targeting capability to IL-11Ralpha after the conjugation of the optical and nuclear tracers. Furthermore, the presence of the metal isotope chelator did not cause quenching of fluorescence emission. The cross validation and direct comparison of optical and nuclear imaging of a tumor was achieved using a single injection, and the preliminary results show the conjugate has tumor targeting capabilities in vivo.

A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Publishing Authors By Initials

W Wang,S Ke,S Kwon,S Yallampalli,AG Cameron,KE Adams,ME Mawad,EM Sevick-Muraca,

For similar cells: cells, cultured: tumor cells, cultured research abstracts see: cells: cells, cultured: tumor cells, cultured research

PUBMED ID PMID:

MEDLINE DATE:

A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Bioconjugate chemistry

VOLUME: 18

Page Numbers: 397-402

Journal Abbreviation: Bioconjug. Chem.

ISSN: 1043-1802

DAY: 22

MONTH: 02

YEAR: 2007

A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9010319

A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Keywords Mesh Terms:

KEYWORDS: Tumor Cells, Cultured

MESH TERMS: metabolism

Chemical & Substance for Abstract: A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Information

Substance Name: Receptors, Interleukin-11

Registry Number: 0

Grant and Affiliation Information for A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain.

AFFILIATION: Department of Radiology, Division of Molecular Imaging, Baylor College of Medicine, Houston, Texas 77030, USA. ww1@bcm.edu

Country: United States

AGENCY: United States NIBIB

GRANT: R01 EB003132

ACRONYM: EB

MEDLINETA: Bioconjug Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain Related Publications

• A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain.
• Biomedical optical tomography using dynamic parameterization and bayesian conditioning on photon migration measurements.
• Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer.
• Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
• Error consideration in contrast-enhanced three-dimensional optical tomography.
• Fluorescence-enhanced optical tomography of a large tissue phantom using point illumination geometries.
• Fluorescence-enhanced three-dimensional lifetime imaging: a phantom study.
• Imaging of fluorescent yield and lifetime from multiply scattered light reemitted from random media.
• Influence of excitation light rejection on forward model mismatch in optical tomography.
• Investigation of static structure factor in dense suspensions by use of multiply scattered light.
• Measurement of particle-size distribution and volume fraction in concentrated suspensions with photon migration techniques.
• Measurement of the fluorescence lifetime in scattering media by frequency-domain photon migration.
• New horizons for imaging lymphatic function.
• Noninvasive quantitative imaging of lymph function in mice.
• Quantitative imaging of lymph function.
• Radiative transport in fluorescence-enhanced frequency domain photon migration.
• Three-dimensional unconstrained and constrained image-reconstruction techniques applied to fluorescence, frequency-domain photon migration.